Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Laihui Luo
Observed name:
Luo, Laihui
Institution:
First Affiliated Hospital of Nanchang University
Observed institutions:
Nanchang University,
First Affiliated Hospital of Jiangxi Medical College,
First Affiliated Hospital of Nanchang University
ORCID:
0000-0003-3351-2187
Observed ORCID:
0000-0003-3351-2187
OpenAlex ID:
A5025199624
Development and Validation of a Nomogram for Predicting Postoperative Early Relapse and Survival in Hepatocellular Carcinoma
2023
·
Yongzhu He
, Laihui Luo
, et al.
·
Journal of the National Comprehensive Cancer Network
·
46
PDF
Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience
2022
·
Laihui Luo
, Yongqiang Xiao
, et al.
·
Frontiers in Oncology
·
42
PDF
Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?
2022
·
Laihui Luo
, Yongzhu He
, et al.
·
Journal of Hepatocellular Carcinoma
·
35
PDF
AURKB targets DHX9 to promote hepatocellular carcinoma progression via PI3K/AKT/mTOR pathway
2024
·
Guoqing Zhu
, Laihui Luo
, et al.
·
Molecular Carcinogenesis
·
20
Postoperative adjuvant transarterial chemoembolisation improves survival of hepatocellular carcinoma patients with microvascular invasion: A multicenter retrospective cohort
2023
·
Laihui Luo
, Renfeng Shan
, et al.
·
United European Gastroenterology Journal
·
19
PDF
Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab
2023
·
Yongqiang Xiao
, Guoqing Zhu
, et al.
·
Journal of Hepatocellular Carcinoma
·
17
PDF
Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China
2023
·
Zhao Wu
, Lifeng Cui
, et al.
·
BMC Cancer
·
17
PDF
Development and validation of nomograms to evaluate the survival outcome of HCC patients undergoing selective postoperative adjuvant TACE
2024
·
Yongzhu He
, Junlin Qian
, et al.
·
La radiologia medica
·
13
Beneficial effects of maintaining liver function during hepatic arterial infusion chemotherapy combined with tyrosine kinase and programmed cell death protein-1 inhibitors on the outcomes of patients with unresectable hepatocellular carcinoma
2024
·
Yongqiang Xiao
, Wei Deng
, et al.
·
BMC Cancer
·
8
Rare benign liver tumors that require differentiation from hepatocellular carcinoma: focus on diagnosis and treatment
2022
·
Laihui Luo
, Tao Wang
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
8
PDF
Prognostic Value of Alpha-Fetoprotein in Unresectable Hepatocellular Carcinoma Treated with Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab
2024
·
Yongqiang Xiao
, Wanqing Chen
, et al.
·
Journal of Hepatocellular Carcinoma
·
6
PDF
The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma
2025
·
Wei Deng
, Jin Xie
, et al.
·
BMC Cancer
·
4
PDF
Membrane attack complex impairs hepatocyte autophagy in alcohol-related liver disease by regulating the SIRT1-FOXO3 signaling
2025
·
Zhigao Hu
, Shanshan Jiang
, et al.
·
Experimental Cell Research
·
1
Development and validation of a nomogram for predicting microvascular invasion and evaluating the efficacy of postoperative adjuvant transarterial chemoembolization
2024
·
Shuju Tu
, Yongzhu He
, et al.
·
Heliyon
Show more works
View as search
Works count:
27
Citation count:
236
H-index:
8
I10-index:
8
Year
Topic
Type